Company creates revolutionary HIV drug

 

A European-based company recently published its findings after treating its first HIV positive patient volunteer in clinical trials with an anti-viral drug aimed at producing long-lasting reductions in patients’ viral loads.

 

ABIVAX’s first-in-class anti-HIV drug’s mechanism of action published April 13 in a peer-reviewed journal, Retrovirology...

 

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here